<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JPP</journal-id>
<journal-id journal-id-type="hwp">spjpp</journal-id>
<journal-title>Journal of Pharmacy Practice</journal-title>
<issn pub-type="ppub">0897-1900</issn>
<issn pub-type="epub">1531-1937</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0897190012442720</article-id>
<article-id pub-id-type="publisher-id">10.1177_0897190012442720</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Adverse Drug Event</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Probable Linezolid-Induced Thrombocytopenia in a Patient With Vancomycin-Resistant Enterococci</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Poulakos</surname>
<given-names>Mara N.</given-names>
</name>
<degrees>PharmD</degrees>
<xref ref-type="corresp" rid="corresp1-0897190012442720"/>
<xref ref-type="aff" rid="aff1-0897190012442720">1</xref></contrib>
<contrib contrib-type="author">
<name>
<surname>Grace</surname>
<given-names>Yasmin</given-names>
</name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff1-0897190012442720">1</xref></contrib>
<contrib contrib-type="author">
<name>
<surname>Coakley</surname>
<given-names>Christina</given-names>
</name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="aff2-0897190012442720">2</xref></contrib>
</contrib-group>
<aff id="aff1-0897190012442720">
<label>1</label>Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA</aff>
<aff id="aff2-0897190012442720">
<label>2</label>VA Medical Center, West Palm Beach, FL, USA</aff>
<author-notes>
<corresp id="corresp1-0897190012442720">Mara N. Poulakos, Gregory School of Pharmacy, Palm Beach Atlantic University, 901 South Flagler Drive, PO Box 24708, West Palm Beach, FL 33416, USA Email: <email>mara_poulakos@pba.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>25</volume>
<issue>6</issue>
<fpage>615</fpage>
<lpage>618</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec>
<title>Purpose:</title>
<p>A probable case of linezolid-induced thrombocytopenia is reported.</p>
</sec>
<sec>
<title>Summary:</title>
<p>A 74-year-old Caucasian male with renal dysfunction was diagnosed with diverticulosis. Patient was prescribed linezolid 600 mg orally twice daily for vancomycin-resistant enterococci abdominal infection that developed secondary to colon resection. Upon initiation of linezolid, platelet count dropped from 248 000 cells/mm<sup>3</sup> on day 1 to 97 000 cells/mm<sup>3</sup> on day 5 of treatment. Linezolid was discontinued and platelet counts improved to pretreatment levels. Application of the Naranjo probability scale indicated a probable association of linezolid therapy and thrombocytopenia. Clinicians should be aware that linezolid has this hematologic side effect and that patients with renal dysfunction are at increased risk. Monitoring platelet count more than once weekly should be advisable in these patients.</p>
</sec>
<sec>
<title>Conclusion:</title>
<p>A 74-year-old Caucasian male with renal dysfunction developed a probable case of linezolid-induced thrombocytopenia after receiving the drug for 5 days for treatment of vancomycin-resistant enterococci abdominal infection.</p>
</sec>
</abstract>
<kwd-group>
<kwd>linezolid</kwd>
<kwd>thrombocytopenia</kwd>
<kwd>adverse reaction</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0897190012442720">
<title>Background</title>
<p>Drug-induced thrombocytopenia (DIT) is an extremely prevalent clinical disorder.<sup><xref ref-type="bibr" rid="bibr1-0897190012442720">1</xref>,<xref ref-type="bibr" rid="bibr2-0897190012442720">2</xref></sup> There are 2 mechanisms of DIT, either immune or nonimmune mediated. Immune-mediated DIT is caused by drug-induced antibodies that combine with the drug or its metabolites to cause destruction of platelets.<sup><xref ref-type="bibr" rid="bibr3-0897190012442720">3</xref></sup> Immune-mediated DIT occurs within 1 to 3 days of drug initiation if the medication had been taken previously and within 7 days if no previous drug exposure.<sup><xref ref-type="bibr" rid="bibr4-0897190012442720">4</xref></sup> In immune-related DIT, platelet counts normalize within a week of discontinuing the drug (range 1-10 days).<sup><xref ref-type="bibr" rid="bibr1-0897190012442720">1</xref>,<xref ref-type="bibr" rid="bibr4-0897190012442720">4</xref></sup> Heparin, antimicrobial (sulfonamides, penicillins, cephalosporins, and vancomycin), diuretic, and anticonvulsant (phenytoin and carbamazepine) agents are examples of drugs that cause thrombocytopenia via platelet destruction. Nonimmune DIT results from bone marrow suppression, which occurs with chemotherapeutic and immunosuppressive agents.<sup><xref ref-type="bibr" rid="bibr5-0897190012442720">5</xref></sup> This type of DIT occurs over several weeks and recovers slowly. Once DIT is suspected, it is necessary to identify and immediately remove the offending agent.</p>
<p>Linezolid is generally well tolerated; most common adverse effects include diarrhea, nausea, vomiting, and headache. Linezolid has been associated with the rare yet severe adverse effect of thrombocytopenia.<sup><xref ref-type="bibr" rid="bibr6-0897190012442720">6</xref></sup> Case reports of linezolid-induced thrombocytopenia have been previously published.<sup><xref ref-type="bibr" rid="bibr7-0897190012442720">7</xref><xref ref-type="bibr" rid="bibr8-0897190012442720"/><xref ref-type="bibr" rid="bibr9-0897190012442720"/><xref ref-type="bibr" rid="bibr10-0897190012442720"/>–<xref ref-type="bibr" rid="bibr11-0897190012442720">11</xref></sup> This case of thrombocytopenia is believed to be associated with linezolid therapy in a patient with vancomycin-resistant enterococci (VRE) abdominal infection.</p>
</sec>
<sec id="section2-0897190012442720">
<title>Case Report</title>
<p>A 74-year-old Caucasian male was admitted with a chief complaint of left lower quadrant pain, nausea, vomiting, and diarrhea for 1 week. The patient was diagnosed by computed tomography of the abdomen and pelvis with diverticulosis for which bowel resection was conducted and a colostomy bag was placed. Patient developed an abdominal infection secondary to colon resection resulting in a prolonged hospital stay. At this point, the patient developed constipation and increased pain. Cultures were positive for <italic>Escherichia coli</italic>, <italic>Candida glabrata</italic>, and VRE; VRE sensitive only to linezolid. The past medical history was significant for depression, alcohol abuse, back pain, transient ischemic attack, hyperlipidemia, and hypertension. His past surgical history included vasectomy and kyphoplasty. Medications on admission included linezolid 600 mg orally (PO) twice daily for VRE, fluconazole 200 mg daily for the systemic fungal infection, oxycodone/acetaminophen 10/325 1 to 2 tablets every (q) 4 hours as needed (pro re nata [prn]) and gabapentin 300 mg PO 3 times a day for pain, escitalopram 10 mg PO daily and clonazepam 0.5 mg PO 2 times a day (BID) for anxiety and depression, haloperidol 5 mg PO daily prn for aggression, lisinopril 20 mg PO daily and metoprolol 25 mg PO BID for hypertension, temazepam 15 mg PO at bedtime (QHS) for insomnia, omeprazole 40 mg PO every morning (QAM) for stress ulcer prophylaxis, and senna 1 tablet PO daily for constipation and enoxaparin 40 mg SC daily for deep venous thrombosis prophylaxis. He had no known drug allergies.</p>
<p>Physical examination on admission was significant for blood pressure 140/64 mm Hg, heart rate (HR) 67 beats/min, temperature 37°C (98.4°F), Respiratory Rate (RR) 18 breaths/min, weight 94.5 kg, and pain 8/10. Otherwise, physical examination was unremarkable. Relevant laboratory data on admission included blood urea nitrogen 40 mg/dL (normal, 7-21 mg/dL), creatinine 1.6 mg/dL (normal, 0.8-1.2 mg/dL), white blood cells 11.4 × 10<sup>3</sup> cells/mm<sup>3</sup> (normal, 3.5-9.6 × 10<sup>3</sup> cells/mm<sup>3</sup>), hemoglobin 8.5 g/dL (normal, 13-16 g/dL), and platelets 235 000 cells/mm<sup>3</sup> (normal, 150 000-450 000 cells/mm<sup>3</sup>). Creatinine clearance, estimated using the Cockcroft-Gault equation, ranged from 40 to 60 mL/min.</p>
<p>On day 1 of linezolid therapy, the patient had a platelet count of 248 000 cells/mm<sup>3</sup>. Platelet count immediately started to fall and on day 5 of linezolid therapy, platelets count was 97 000 cells/mm<sup>3</sup>. Subsequently, culture and sensitivity report of the abdominal fluid were positive for <italic>Pseudomonas aeruginosa</italic> sensitive to ceftazidime. Linezolid was discontinued and patient was on ceftazidime and metronidazole. Platelet count improved to pretreatment levels with the discontinuation of linezolid. <xref ref-type="fig" rid="fig1-0897190012442720">Figure 1</xref> illustrates the changes in platelet count over time.</p>
<fig id="fig1-0897190012442720" position="float">
<label>Figure 1.</label>
<caption>
<p>Course of probable linezolid-induced thrombocytopenia.</p>
</caption>
<graphic xlink:href="10.1177_0897190012442720-fig1.tif"/>
</fig>
</sec>
<sec id="section3-0897190012442720">
<title>Discussion</title>
<p>Linezolid has been associated with time-dependent thrombocytopenia. In phase III clinical trials, the rate of thrombocytopenia was 2.4% (ranged from 0.3% to 10%).<sup><xref ref-type="bibr" rid="bibr6-0897190012442720">6</xref></sup> The rate of thrombocytopenia (defined as platelet counts ≤100 000 cells/mm<sup>3</sup>) in postmarketing studies was found to be higher (ranged from 1.5% to 32%) than in phase III trials.<sup><xref ref-type="bibr" rid="bibr12-0897190012442720">12</xref><xref ref-type="bibr" rid="bibr13-0897190012442720"/><xref ref-type="bibr" rid="bibr14-0897190012442720"/><xref ref-type="bibr" rid="bibr15-0897190012442720"/><xref ref-type="bibr" rid="bibr16-0897190012442720"/><xref ref-type="bibr" rid="bibr17-0897190012442720"/>–<xref ref-type="bibr" rid="bibr18-0897190012442720">18</xref></sup> One reason for the higher rates of thrombocytopenia in postmarketing surveillance is explained by the fact that these studies included patients with comorbidities, end-organ failure who may have been excluded from phase III trials. Thrombocytopenia occurred more frequently with prolonged use (greater than 14 days) of linezolid therapy.<sup><xref ref-type="bibr" rid="bibr13-0897190012442720">13</xref></sup> The duration of linezolid treatment in most phase III trials was ≤14 days, whereas in postmarketing studies treatment often exceeded 2 weeks. This further explains the differences in the reported rates of thrombocytopenia between phase III trials and postmarketing surveillance. Fortunately, linezolid-induced thrombocytopenia is reversible upon discontinuation of the drug.<sup><xref ref-type="bibr" rid="bibr11-0897190012442720">11</xref>,<xref ref-type="bibr" rid="bibr19-0897190012442720">19</xref></sup>
</p>
<p>In our patient case, we attributed thrombocytopenia to linezolid since platelet count had been stable on long-term daily medication regimen until the introduction of linezolid. The rapid decrease in platelet count following exposure to linezolid and its resolution upon discontinuation of the drug supported a drug-induced cause (<xref ref-type="fig" rid="fig1-0897190012442720">Figure 1</xref>). The Naranjo probability scale for adverse drug reactions was used in the present case to determine the likelihood of association between linezolid therapy and thrombocytopenia.<sup><xref ref-type="bibr" rid="bibr20-0897190012442720">20</xref></sup> Our patient met criteria for a score of 7, suggesting probable association.</p>
<p>Our case findings were similar to 2 cases reported by Pascoalinho et al, in which a 79-year-old female with methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) and a 87-year-old male with septic shock were both treated with linezolid and had their platelet counts decrease just 24 hours after starting the therapy.<sup><xref ref-type="bibr" rid="bibr7-0897190012442720">7</xref></sup> Time to recovery of platelets in our case (4 days) was faster than that reported by Pascoalinho. Platelet count started to increase 6 days after discontinuation of therapy in case 1 and after 2 days in case 2. Platelet counts normalized after 11 days in case 1 and 7 days in case 2. Patient’s serum in both cases was tested and found to be positive for the presence of linezolid-related antibodies against platelets.<sup><xref ref-type="bibr" rid="bibr7-0897190012442720">7</xref></sup> In a case (66-year-old man developed sternal osteomyelitis) of linezolid-induced thrombocytopenia reported by Waldrep et al and in the 3 cases (ages 43-70 years) reported by Green et al, patients had MRSA infection and experienced transient thrombocytopenia that resolved 7 to 10 days after drug was discontinued.<sup><xref ref-type="bibr" rid="bibr8-0897190012442720">8</xref>,<xref ref-type="bibr" rid="bibr9-0897190012442720">9</xref></sup>
</p>
<p>In this case and a number of other cases involved elderly patients (60 years old or older) receiving linezolid 600 mg twice daily.<sup><xref ref-type="bibr" rid="bibr7-0897190012442720">7</xref>,<xref ref-type="bibr" rid="bibr9-0897190012442720">9</xref><xref ref-type="bibr" rid="bibr10-0897190012442720"/>–<xref ref-type="bibr" rid="bibr11-0897190012442720">11</xref></sup> Age did not significantly affect linezolid’s pharmacokinetics with single 600 mg oral doses.<sup><xref ref-type="bibr" rid="bibr21-0897190012442720">21</xref></sup> In addition, our patient had renal dysfunction (creatinine clearance ranged from 40 to 60 mL/min). The clearance of linezolid is also not affected by decreased renal function; linezolid concentrations in patients with renal impairment were similar to those in healthy patients.<sup><xref ref-type="bibr" rid="bibr22-0897190012442720">22</xref></sup> Therefore, a dose adjustment is not necessary for patients with renal dysfunction or for elderly patients (65 years or older).<sup><xref ref-type="bibr" rid="bibr1-0897190012442720">1</xref></sup> Renal insufficiency is known to cause thrombocytopenia.<sup><xref ref-type="bibr" rid="bibr23-0897190012442720">23</xref>,<xref ref-type="bibr" rid="bibr24-0897190012442720">24</xref></sup> Although the use of linezolid is not precluded in patients with renal impairment, episodes of severe thrombocytopenia are more likely to occur in these patients. The incidence of linezolid-induced thrombocytopenia (platelet counts &lt;100 000 cells/mm<sup>3</sup>) reported in studies among patients with renal dysfunction was higher (ranged from 65% to 79%) than that reported in patients without renal dysfunction (36-43%).<sup><xref ref-type="bibr" rid="bibr25-0897190012442720">25</xref>,<xref ref-type="bibr" rid="bibr26-0897190012442720">26</xref></sup> Patients with end-stage renal disease had a 1.83 times higher incidence rate of thrombocytopenia compared to those with normal renal function, and the risk significantly increased with glomerular filtration rates &lt;50 mL/min.<sup><xref ref-type="bibr" rid="bibr27-0897190012442720">27</xref><xref ref-type="bibr" rid="bibr28-0897190012442720"/>–<xref ref-type="bibr" rid="bibr29-0897190012442720">29</xref></sup>
</p>
<p>The mechanism of linezolid-induced hematological effects needs further study. Bernstein et al suggested immune-mediated platelet destruction.<sup><xref ref-type="bibr" rid="bibr11-0897190012442720">11</xref></sup> Linezolid is oxidized into 2 inactive metabolites, PNU-142586 and PNU-142300.<sup><xref ref-type="bibr" rid="bibr30-0897190012442720">30</xref></sup> Patients with renal insufficiency have 10-fold higher concentrations of these metabolites than healthy subjects.<sup><xref ref-type="bibr" rid="bibr22-0897190012442720">22</xref>,<xref ref-type="bibr" rid="bibr31-0897190012442720">31</xref></sup> The significance of the accumulation of these metabolites on the destruction of platelets needs to be studied further.</p>
<p>The package insert recommends that platelet counts should be monitored weekly in patients on linezolid therapy.<sup><xref ref-type="bibr" rid="bibr1-0897190012442720">1</xref></sup> Clinicians placing patients with renal impairment (creatinine clearance &lt;60 mL/min) on linezolid therapy should have platelet counts monitored more than once weekly.<sup><xref ref-type="bibr" rid="bibr26-0897190012442720">26</xref></sup>
</p>
</sec>
<sec id="section4-0897190012442720">
<title>Conclusion</title>
<p>A 74-year-old male with VRE developed a probable case of linezolid-induced thrombocytopenia. Clinicians should be aware of this adverse effect and that patients with renal dysfunction are at increased risk. Platelet count monitoring more than once weekly should be advised in patients with renal impairment.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0897190012442720"><label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0897190012442720"><label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0897190012442720">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>George</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Raskob</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>SR</given-names>
</name>
<etal/>
</person-group> <article-title>Drug-induced thrombocytopenia: a systematic review</article-title> <article-title>of published case reports</article-title>. <source>Ann Intern Med</source>. <year>1998</year>;<volume>129</volume>(<issue>11</issue>):<fpage>886</fpage>–<lpage>890</lpage>.</citation>
</ref>
<ref id="bibr2-0897190012442720">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swisher</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Vesely</surname>
<given-names>SK</given-names>
</name>
<etal/>
</person-group> <article-title>Drug-induced thrombocytopenia: an updated systematic review</article-title>. <source>Drug Saf</source>. <year>2009</year>;<volume>32</volume>(<issue>1</issue>):<fpage>85</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr3-0897190012442720">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aster</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bougie</surname>
<given-names>DW</given-names>
</name>
</person-group>. <article-title>Drug-induced immune thrombocytopenia</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>(<issue>6</issue>):<fpage>580</fpage>–<lpage>587</lpage>.</citation>
</ref>
<ref id="bibr4-0897190012442720">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Visentin</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>CY</given-names>
</name>
</person-group>. <article-title>Drug induced thrombocytopenia</article-title>. <source>Hematol Oncol Clin North Am</source>. <year>2007</year>;<volume>21</volume>(<issue>4</issue>):<fpage>685</fpage>–<lpage>696</lpage>.</citation>
</ref>
<ref id="bibr5-0897190012442720">
<label>5</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Aster</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Drug-induced thrombocytopenia</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Michelson</surname>
<given-names>AD</given-names>
</name>
</person-group>, ed. <source>Platelets</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Academic Press</publisher-name>; <year>2007</year>:<fpage>887</fpage>–<lpage>902</lpage>.</citation>
</ref>
<ref id="bibr6-0897190012442720">
<label>6</label>
<citation citation-type="book">
<collab collab-type="author">Pfizer Inc</collab>. <source>Zyvox (linezolid) Product Information</source>. <publisher-loc>Pharmacia &amp; Upjohn Company. Division of Pfizer Inc</publisher-loc>: <publisher-name>New York</publisher-name>, <publisher-loc>NY</publisher-loc>; <year>2010</year>.</citation>
</ref>
<ref id="bibr7-0897190012442720">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pascoalinho</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vilas</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Coelho</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>Linezolid-related immune-mediated severe thrombocytopenia</article-title>. <source>Int J Antimicrob Agents</source>. <year>2011</year>;<volume>37</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr8-0897190012442720">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Green</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Maddox</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Huttenbach</surname>
<given-names>ED</given-names>
</name>
</person-group>. <article-title>Linezolid and reversible myelosuppression</article-title>. <source>JAMA</source>. <year>2001</year>;<volume>285</volume>(<issue>10</issue>):<fpage>1291</fpage>.</citation>
</ref>
<ref id="bibr9-0897190012442720">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waldrep</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Skiest</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>Linezolid-induced anemia and thrombocytopenia</article-title>. <source>Pharmacotherapy</source>. <year>2002</year>;<volume>22</volume>(<issue>1</issue>):<fpage>109</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr10-0897190012442720">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lakhani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Bombassaro</surname>
<given-names>AM</given-names>
</name>
</person-group>. <article-title>Probable linezolid-induced pancytopenia</article-title>. <source>Can J Infect Dis Med Microbiol</source>. <year>2005</year>;<volume>16</volume>(<issue>5</issue>):<fpage>286</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr11-0897190012442720">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernstein</surname>
<given-names>WB</given-names>
</name>
<name>
<surname>Trotta</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Rector</surname>
<given-names>JT</given-names>
</name>
<etal/>
</person-group> <article-title>Mechanisms for linezolid-induced anemia and thrombocytopenia</article-title>. <source>Ann Pharmacother</source>. <year>2003</year>;<volume>37</volume>(<issue>4</issue>):<fpage>517</fpage>–<lpage>520</lpage>.</citation>
</ref>
<ref id="bibr12-0897190012442720">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuter</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Tillotson</surname>
<given-names>GS</given-names>
</name>
</person-group>. <article-title>Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid</article-title>. <source>Pharmacotherapy</source>. <year>2001</year>;<volume>21</volume>(<issue>8</issue>):<fpage>1010</fpage>–<lpage>1013</lpage>.</citation>
</ref>
<ref id="bibr13-0897190012442720">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gerson</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Bruss</surname>
<given-names>JB</given-names>
</name>
<etal/>
</person-group> <article-title>Hematologic effects of linezolid: summary of clinical experience</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2002</year>;<volume>46</volume>(<issue>8</issue>):<fpage>2723</fpage>–<lpage>2726</lpage>.</citation>
</ref>
<ref id="bibr14-0897190012442720">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minson</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Gentry</surname>
<given-names>CA</given-names>
</name>
</person-group>. <article-title>Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center</article-title>. <source>Pharmacotherapy</source>. <year>2010</year>;<volume>30</volume>(<issue>9</issue>):<fpage>895</fpage>–<lpage>903</lpage>.</citation>
</ref>
<ref id="bibr15-0897190012442720">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niwa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sakakibara</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy</article-title>. <source>Clin Ther</source>. <year>2009</year>;<volume>31</volume>(<issue>10</issue>):<fpage>2126</fpage>–<lpage>2133</lpage>.</citation>
</ref>
<ref id="bibr16-0897190012442720">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orrick</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Johns</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Janelle</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Thrombocytopenia secondary to linezolid administration: what is the risk?</article-title> <source>Clin Infect Dis</source>. <year>2002</year>;<volume>35</volume>(<issue>3</issue>):<fpage>348</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr17-0897190012442720">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bishop</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Melvani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Howden</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Charles</surname>
<given-names>PGP</given-names>
</name>
<name>
<surname>Grayson</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2006</year>;<volume>50</volume>(<issue>4</issue>):<fpage>1599</fpage>–<lpage>1602</lpage>.</citation>
</ref>
<ref id="bibr18-0897190012442720">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Attassi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hershberger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Alam</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Thrombocytopenia associated with linezolid therapy</article-title>. <source>Clin Infect Dis</source>. <year>2002</year>;<volume>34</volume>(<issue>5</issue>):<fpage>695</fpage>–<lpage>698</lpage>.</citation>
</ref>
<ref id="bibr19-0897190012442720">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubinstein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Isturiz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Standiford</surname>
<given-names>HC</given-names>
</name>
<etal/>
</person-group> <article-title>Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2003</year>;<volume>47</volume>(<issue>6</issue>):<fpage>1824</fpage>–<lpage>1831</lpage>.</citation>
</ref>
<ref id="bibr20-0897190012442720">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naranjo</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Busto</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Sellers</surname>
<given-names>EM</given-names>
</name>
<etal/>
</person-group> <article-title>A method for estimating the probability of adverse drug reactions</article-title>. <source>Clin Pharmacol Ther</source>. <year>1981</year>;<volume>30</volume>(<issue>2</issue>):<fpage>239</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr21-0897190012442720">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sisson</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Jungbluth</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>NK</given-names>
</name>
</person-group>. <article-title>Age and sex effects on the pharmacokinetics of linezolid</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2002</year>;<volume>57</volume>(<issue>11</issue>):<fpage>793</fpage>–<lpage>797</lpage>.</citation>
</ref>
<ref id="bibr22-0897190012442720">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brier</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Stalker</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Aronoff</surname>
<given-names>GR</given-names>
</name>
<etal/>
</person-group> <article-title>Pharmacokinetics of linezolid in subjects with renal dysfunction</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2003</year>;<volume>47</volume>(<issue>9</issue>):<fpage>2775</fpage>–<lpage>2780</lpage>.</citation>
</ref>
<ref id="bibr23-0897190012442720">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonomini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sirolli</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Uremic toxicity and anemia</article-title>. <source>J Nephrol</source>. <year>2003</year>;<volume>16</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr24-0897190012442720">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stewart</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>Platelet numbers and life span in acute and chronic renal failure</article-title>. <source>Thromb Diath Haemorrh</source>. <year>1967</year>;<volume>17</volume>(<issue>3-4</issue>):<fpage>532</fpage>–<lpage>542</lpage>.</citation>
</ref>
<ref id="bibr25-0897190012442720">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>IJ</given-names>
</name><etal/>
</person-group> <article-title>High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency</article-title>. <source>Int J Antimicrob Agents</source>. <year>2006</year>;<volume>28</volume>(<issue>4</issue>):<fpage>345</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr26-0897190012442720">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takeshita</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Renal function as a predictor of linezolid induced thrombocytopenia</article-title>. <source>Int J Antimicrob Agents</source>. <year>2009</year>;<volume>33</volume>(<issue>1</issue>):<fpage>98</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr27-0897190012442720">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>CY</given-names>
</name>
<etal/>
</person-group> <article-title>High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease</article-title>. <source>Clin Infect Dis</source>. <year>2006</year>;<volume>42</volume>(<issue>1</issue>):<fpage>66</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr28-0897190012442720">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rao</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>CW</given-names>
</name>
</person-group>. <article-title>Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series</article-title>. <source>Diagn Microbiol Infect Dis</source>. <year>2007</year>;<volume>59</volume>(<issue>2</issue>):<fpage>173</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr29-0897190012442720">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soriano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ortega</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2007</year>;<volume>51</volume>(<issue>7</issue>):<fpage>2559</fpage>–<lpage>2563</lpage>.</citation>
</ref>
<ref id="bibr30-0897190012442720">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhanel</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Shroeder</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vercaigne</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group> <article-title>A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins</article-title>. <source>Can J Infect Dis</source>. <year>2001</year>;<volume>12</volume>(<issue>6</issue>):<fpage>379</fpage>–<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr31-0897190012442720">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stalker</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Jungbluth</surname>
<given-names>GL</given-names>
</name>
</person-group>. <article-title>Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial</article-title>. <source>Clin Pharmacokinet</source>. <year>2003</year>;<volume>42</volume>(<issue>13</issue>):<fpage>1129</fpage>–<lpage>1140</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>